Marksans Pharma Ltd

Marksans Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Marksans Pharma Ltd

₹ 249 -2.17%
27 May - close price
marksanspharma.com BSE: 524404 NSE: MARKSANS
About

Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products [1]

Key Points

Product Portfolio
OTC Products: (74% of FY24 revenue)
Include Pain Management, Cough and Cold, Digestive Remedies, Vitamins and Tonics, Skin Treatments, and Allergies.[1]
Prescription (Rx) Products: (26%)[2]
Includes cardiovascular, central nervous system (CNS), anti-allergic, anticancer, and anti-diabetic drugs.

Website BSE NSE
  • Market Cap ₹ 11,296 Cr.
  • Current Price ₹ 249
  • High / Low ₹ 271 / 155
  • Stock P/E 37.6
  • Book Value ₹ 36.5
  • Dividend Yield 0.32 %
  • ROCE 25.7 %
  • ROE 19.8 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has delivered good profit growth of 25.0% CAGR over last 5 years

Cons

  • Company has high debtors of 170 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare Nifty Microcap 250 Nifty Total Market BSE 1000 Nifty Smallcap 500

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
153 182 205 241 225 255 309 312 299 320 320 340 362
130 155 167 199 191 213 245 252 248 250 248 264 256
Operating Profit 23 27 37 42 34 41 63 60 52 70 72 75 106
OPM % 15% 15% 18% 17% 15% 16% 21% 19% 17% 22% 22% 22% 29%
4 33 16 1 12 8 20 23 7 2 58 16 27
Interest 1 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 4 5 8 8 7 7 7 7 8 8 8 9 9
Profit before tax 23 54 44 35 38 42 76 75 50 64 121 82 124
Tax % 22% 19% 30% 27% 14% 24% 17% 26% 25% 24% 18% 26% 26%
18 44 31 25 33 32 63 55 38 48 100 61 92
EPS in Rs 0.39 0.98 0.69 0.56 0.73 0.71 1.39 1.22 0.83 1.06 2.20 1.34 2.03
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
406 358 216 295 424 433 600 658 655 853 1,174 1,341
290 254 191 266 361 362 486 545 563 713 970 1,018
Operating Profit 116 104 24 29 63 71 114 114 92 140 204 324
OPM % 29% 29% 11% 10% 15% 16% 19% 17% 14% 16% 17% 24%
3 9 7 7 8 0 31 42 60 62 70 104
Interest 13 6 4 8 7 7 5 4 4 1 1 1
Depreciation 9 15 15 12 9 12 15 18 17 29 29 34
Profit before tax 97 92 12 17 56 53 124 135 132 172 243 392
Tax % 31% 22% 3% 25% 22% 28% 21% 23% 22% 22% 23% 23%
67 71 12 12 44 38 98 104 103 134 188 301
EPS in Rs 1.64 1.75 0.28 0.30 1.07 0.93 2.40 2.54 2.27 2.95 4.15 6.64
Dividend Payout % 7% 7% 18% 16% 5% 11% 10% 10% 22% 20% 19% 0%
Compounded Sales Growth
10 Years: 14%
5 Years: 17%
3 Years: 27%
TTM: 14%
Compounded Profit Growth
10 Years: 15%
5 Years: 25%
3 Years: 43%
TTM: 60%
Stock Price CAGR
10 Years: 19%
5 Years: 28%
3 Years: 49%
1 Year: 0%
Return on Equity
10 Years: 13%
5 Years: 15%
3 Years: 16%
Last Year: 20%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 41 41 41 41 41 41 41 41 45 45 45 45
Reserves 305 369 378 388 430 465 559 744 1,066 1,177 1,338 1,607
62 53 73 67 78 11 14 14 8 8 11 12
119 71 54 61 64 83 127 167 226 285 361 330
Total Liabilities 527 534 546 557 612 600 741 966 1,345 1,516 1,755 1,994
90 97 94 88 103 115 129 136 144 272 383 398
CWIP 0 0 0 0 0 0 0 0 4 0 0 0
Investments 68 231 234 236 236 236 236 237 266 293 266 267
369 205 217 233 273 249 375 594 931 952 1,105 1,329
Total Assets 527 534 546 557 612 600 741 966 1,345 1,516 1,755 1,994

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
112 65 -14 16 20 108 107 56 52 34 31 211
-29 -177 -8 -8 -20 -24 9 -128 -195 -114 17 -140
51 -52 21 -10 1 -82 -14 71 210 -26 -30 -39
Net Cash Flow 134 -164 -1 -2 1 2 102 -1 67 -106 18 32
Free Cash Flow 80 43 -25 10 -4 83 86 33 16 -121 -89 163
CFO/OP 124% 82% -56% 70% 52% 165% 112% 77% 91% 52% 38% 88%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 112 136 262 209 153 136 103 137 170 158 171 170
Inventory Days 85 90 95 91 109 111 101 100 121 145 117 102
Days Payable 75 64 67 73 58 84 69 72 103 122 116 97
Cash Conversion Cycle 123 161 290 228 204 163 135 165 188 182 172 174
Working Capital Days 29 91 177 149 127 144 90 110 143 144 145 150
ROCE % 33% 22% 3% 5% 12% 11% 23% 20% 14% 15% 19% 26%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2025
R&D Spend as % of Sales
%

Log in to view insights

Please log in to see hidden values.

Login
Total Manufacturing Capacity
Billion units p.a.
Number of SKUs
Number
ANDA/MA Approved (Cumulative)
Number
Working Capital Cycle
Days
Number of Countries Presence
Number
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
43.85% 43.85% 43.85% 43.85% 43.87% 43.87% 43.87% 43.87% 43.87% 43.87% 43.87% 43.87%
14.90% 15.07% 15.55% 15.57% 18.59% 21.31% 21.95% 22.19% 19.89% 16.92% 8.13% 16.76%
3.65% 4.02% 4.76% 5.17% 3.75% 4.10% 4.30% 4.55% 5.50% 5.28% 5.91% 6.57%
37.60% 37.06% 35.81% 35.40% 33.77% 30.70% 29.88% 29.37% 30.74% 33.93% 42.08% 32.78%
No. of Shareholders 1,88,4472,07,9372,37,3772,54,6992,35,5002,48,8452,59,8132,57,2732,56,2212,65,7882,55,1532,46,279

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls